EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)LeserbriefRandomisierte kontrollierte Studie

Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD

Elisa Fabbrini, Brian Rady, Anastasiya Koshkina, Jae Yoon Jeon, Vivaswath S Ayyar, Cynthia Gargano, Nicholas DiProspero, Susan Wendel, Julia Hegge, Holly Hamilton, Zhi-Ming Ding, Maria Afrazi und 16 weitere

New England Journal of Medicine · 2024

DOI: 10.1056/nejmc2402341 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Elisa Fabbrini und 27 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Research and Development, Raritan, NJ elifabbrini@gmail.com. Hauptthemen laut MEDLINE: Homozygote, RNA, Small Interfering, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 3 Literaturangaben. Gefördert von: Johnson & Johnson Innovative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HomozygoteRNA, Small InterferingNon-alcoholic Fatty Liver DiseaseAdultFemaleHumansMaleAcyltransferasesMutationPhospholipases A2, Calcium-IndependentPolymorphism, Single NucleotideLiverPrecision MedicineProof of Concept StudyYoung AdultMiddle AgedAged

Substanzen

AcyltransferasesPhospholipases A2, Calcium-IndependentPNPLA3 protein, humanRNA, Small Interfering

Autor:innen und Institutionen

  • Janssen Research and Development, Raritan, NJ elifabbrini@gmail.com.
  • Janssen Research and Development, Spring House, PA.
  • Janssen Research and Development, Raritan, NJ.
  • Arrowhead Pharmaceuticals, Pasadena, CA.
  • Janssen Pharmaceutical, Tokyo, Japan.
  • Endeavor Clinical Trials, San Antonio, TX.

Förderung

  • Johnson & Johnson Innovative Medicine

Zitieren

APA

Fabbrini, E., Rady, B., Koshkina, A., Jeon, J. Y., Ayyar, V. S., Gargano, C., DiProspero, N., Wendel, S., Hegge, J., Hamilton, H., Ding, Z. M., Afrazi, M., Nicholas, A., Pei, T., Nakano, M., Ouchi, S., Saito, Y., Yamashita, A., Tamamura, R., …, & Makimura, H. (2024). Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD. New England Journal of Medicine. https://doi.org/10.1056/nejmc2402341

Vancouver

Fabbrini E, Rady B, Koshkina A, Jeon JY, Ayyar VS, Gargano C, et al. Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD. New England Journal of Medicine. 2024. doi:10.1056/nejmc2402341

BibTeX
@article{Fabbrini2024,
  author = {Fabbrini, Elisa and Rady, Brian and Koshkina, Anastasiya and Jeon, Jae Yoon and Ayyar, Vivaswath S and Gargano, Cynthia and DiProspero, Nicholas and Wendel, Susan and Hegge, Julia and Hamilton, Holly and Ding, Zhi-Ming and Afrazi, Maria and Nicholas, Anthony and Pei, Tao and Nakano, Masayoshi and Ouchi, Shohei and Saito, Yuki and Yamashita, Aimi and Tamamura, Ryo and Salazar, Hernan and Shapiro, Craig and Yoshihara, Tatsuya and Yonemura, Takuma and Inoue, Satoshi and Matsuoka, Osamu and Erion, Mark and Pocai, Alessandro and Makimura, Hideo},
  title = {Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD},
  journal = {New England Journal of Medicine},
  year = {2024},
  doi = {10.1056/nejmc2402341}
}
Kostenlos starten →